Urotoday International Journal

Home > Current issue

UIJ - Definition of BCG Failure in Non-Muscle Invasive Bladder Cancer in Major Urological Guidelines

Mohamed H Kamel1, Sarabeth L Bailey1, John T Moore1, Samy M Heshmat1, Nabil Bissada, MD1

1 Department of Urology, University of Arkansas for Medical Sciences. Little Rock Arkansas USA.

Date Received September 09, 2011
Accepted on November 09, 2011
Original Publication Date November 30, 2011
E-mail

ABSTRACT

Bladder cancer (BC) is the fifth most commonly diagnosed cancer in the nation. Radical cystectomy (RC) is the most effective treatment for locally advanced bladder cancer and is a formidable operation. The perioperative mortality in high-volume centers ranges from 0.7 to 5.6%. Thus, when faced with this diagnosis, there is a desire to pursue a bladder-preserving strategy and avoid RC. One treatment for HG Ta/T1, and carcinoma in situ (CIS) is intravesical bacillus Calmette-Guérin (BCG) therapy. Many studies have confirmed its value in reducing tumor recurrence following transurethral resection of bladder tumors (TURBT). After reviewing the various guidelines, we summarize our recommendations for defining BCG failure.

KEYWORDS: Bladder; Cancer; BCG; Guidelines

CORRESPONDENCE: Mohamed H Kamel, MD, Assistant Professor, Urologic Oncologist, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, Arkansas, 72205 (mkamel@uams.edu).

CITATION: UroToday Int J. 2011 Dec;4(6):art 82. http://dx.doi.org/10.3834/uij.1944-5784.2011.12.15

Login to view this Article.Login Here

Abstract | Download Citation | Full Text

case diagnosis

Participate Now
CME - Frequently Asked Questions in Improving Detection and Initial Treatment of Bladder Cancer


Presented by the Warren Alpert Medical School of Brown University, Office of Continuing Medical Education.

Target Audience

This activity is designed for urologists and other healthcare professionals interested in or involved with the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be able to:

  1. Discuss the epidemiology of bladder cancer including prevalence, mortality, and risk factors
  2. Describe the economic impact of bladder cancer and how improved techniques for initial detection and at the time of transurethral resection of bladder tumor (TURBT) may decrease the economic burden
  3. Compare and contrast new urine biomarkers when compared to urine cytology
  4. Discuss the role of photodynamic diagnosis using hexaminolevulinate-guided fluorescence cystoscopy in detecting carcinoma in situ and residual disease at the time of TURBT compared to traditional white-light cystoscopy (WLC)
  5. Optimize use of intravesical therapy after TURBT to prevent recurrence of bladder...
    Take CME
CME - Frequently Asked Questions in the Management of Castrate-Resistant Prostate Cancer (CRPC)

An Expert Panel Interview

Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Identify patients with castrate-resistant prostate cancer (CRPC)

  • Review current and future modalities available for the treatment of CRPC.

  • Discuss therapeutic strategies that may mitigate skeletal adverse events associated with metastatic prostate cancer and its treatment.

  • Program Release: April 1, 2011

  • Program Expiration: April 30, 2012

  • Estimated time to complete: 60 minutes

  • There are no prerequisites for participation.

  • 1 AMA PRA Category 1 Credit™

  • Educational grant provided by Amgen Inc and Dendreon Corporation.

Take CME
mobile news
Visit our mobile news channel today and get the latest Urological reviews, conference coverage, surgical techniques, clinical updates and more!